Consensus United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
319 ^USD	+0.03%		+4.25%	+45.09%

25/06	Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension	MT
25/06	Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension	CI

Evolution of the average Target Price on United Therapeutics Corporation

Price target over the last 5 years

History of analyst recommendation changes

514968ac4c6d.CwDCV6CcYVhEGUlOir_rJVErD5CJqbkoGPaUmelmVrw.cWq4Ie7lMWB0WH03wJKibBNpTvP80OZxYKzbzLYwJPBFMaE6kdEMdQNREA~e7cc117540172da87e94e89f7008fcc3

Analyst Recommendations on United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing	18/06	MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing	15/06	MT
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating	12/06	MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction	03/06	MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing	17/05	MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing	15/05	MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing	11/05	MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing	09/05	MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing	08/05	MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing	07/05	MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing	07/05	MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	04/05	MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	02/05	MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating	02/05	MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	20/04	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	18/04	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	16/04	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	12/04	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	10/04	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	06/04	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	05/04	MT
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing	26/03	MT
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing	23/03	MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing	22/03	MT
Goldman Sachs Upgrades United Therapeutics to Neutral From Sell, Adjusts PT to $215 From $213	12/02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

319 USD

Average target price

295.9 USD

Spread / Average Target

-7.24%

High Price Target

400 USD

Spread / Highest target

+25.38%

Low Price Target

220 USD

Spread / Lowest Target

-31.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering United Therapeutics Corporation

Wells Fargo Securities
UBS
Oppenheimer
Goldman Sachs
Leerink Partners
Wedbush
Morgan Stanley
Ladenburg Thalmann
Argus
Credit Suisse
HC Wainwright
JPMorgan Chase
Jefferies & Co.
BTIG
J.P. Morgan Chase

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar